01Jul
Novartis and Alcon FCPA Enforcement Action: Lessons Learned (Part III of III)
At the outset, Novartis is “lucky” – the settlement is relatively positive, despite its 2016 SEC enforcement action in China. Given Novartis weak culture of compliance (if anything, a better description may be a culture of non-compliance) and its status as a recidivist, Novartis could have been slammed with a stiffer enforcement action, including assignment of an independent corporate compliance monitor and a higher penalty. ...
By:
Michael Volkov
Related
On January 31, 2020, U.S. Citizenship and Immigration Services (USCIS) published a new version of Fo...
Read More >
On December 16, 2019, the National Labor Relations Board (NLRB) issued a major decision restoring em...
Read More >
I always say that the retirement plan business is relationship-driven. It’s a business built on tru...
Read More >
A hearing is set for Thursday on draft legislation to “fix” a bill that had been earlier vetoed an...
Read More >
Following closely on its release of guidance for higher education institutions, and its promise of a...
Read More >
Rock Health called the landmark Teladoc-Livongo deal a starter pistol for the virtual care platform ...
Read More >